학술논문
Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report
Document Type
Article
Author
Source
Intestinal research (Intest Res). Jan 30, 2022 20(1):150
Subject
Language
Korean
English
English
ISSN
1598-9100
Abstract
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19. (Intest Res 2022;20:150-155)